Paxlovid as a potential treatment for long COVID
MW McCarthy - Expert Opinion on Pharmacotherapy, 2023 - Taylor & Francis
ABSTRACT Introduction On 31 July 2023, the United States Department of Health and
Human Services announced the formation of the Office of Long COVID Research and …
Human Services announced the formation of the Office of Long COVID Research and …
COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned
RM Gulick, AK Pau, E Daar, L Evans… - Annals of Internal …, 2024 - acpjournals.org
Description: In March 2020, the White House Coronavirus Task Force determined that
clinicians in the United States needed expert treatment guidelines to optimally manage …
clinicians in the United States needed expert treatment guidelines to optimally manage …
Virus-induced acute respiratory distress syndrome causes cardiomyopathy through eliciting inflammatory responses in the heart
BACKGROUND: Viral infections can cause acute respiratory distress syndrome (ARDS),
systemic inflammation, and secondary cardiovascular complications. Lung macrophage …
systemic inflammation, and secondary cardiovascular complications. Lung macrophage …
[HTML][HTML] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
[HTML][HTML] Inflammation: Is It a Healer, Confounder, or a Promoter of Cardiometabolic Risks?
AR Tate, GHR Rao - Biomolecules, 2024 - mdpi.com
Inflammation is the body's non-specific response to injury or infection. It is a natural defense
mechanism that helps to maintain homeostasis and promotes tissue repair. However …
mechanism that helps to maintain homeostasis and promotes tissue repair. However …
Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 …
J Yazdany, A Ware, ZS Wallace, S Bhana… - Arthritis Care & …, 2024 - Wiley Online Library
Objective Approximately one third of individuals worldwide have not received a COVID‐19
vaccine. Although studies have investigated risk factors linked to severe COVID‐19 among …
vaccine. Although studies have investigated risk factors linked to severe COVID‐19 among …
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
Clinical review of COVID-19; pathogenesis, diagnosis, and management
Severe acute respiratory syndrome-coronavirus (SARS-CoV-2, or COVID-19 virus) is a
worldwide pandemic pathogen infecting 210 territories. It belongs to the family …
worldwide pandemic pathogen infecting 210 territories. It belongs to the family …
[HTML][HTML] Antiviral efficacy of fluoxetine in early symptomatic COVID-19: An open-label, randomised, controlled, adaptive platform trial (PLATCOV)
P Jittamala, S Boyd, WHK Schilling, JA Watson… - …, 2025 - thelancet.com
Background The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine
were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro …
were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro …